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A B S T R A C T The presence of human thyroglobulin (HTg) in serum of patients with differentiated thyroid carcinoma was studied. The thyroglobulin detected in the serum of such patients was identical by immunological criteria to the serum standard used in the radioimmunoassay. The serum thyroglobulin levels in untreated patients with differentiated thyroid carcinoma ranged from 22.0 to 445.0 ng/ml with a mean of 144.3± 46.5 ng/ml (SEM) (n = 10). The mean serum thyroglobulin measured postoperatively in seven of these patients was 6 .4±+1.5 ng/ml, not statistically different from the mean level of 5.1±0.49 ng/ml (range 0-20.7 ng/ml) observed in 71 out of 95 control subjects with detectable HTg levels. By contrast serum HTg levels were normal or undetectable in subjects with medullary carcinoma of the thyroid. HTg levels were within normal limits in sera of patients who had previously undergone successful therapy for a differentiated thyroid carcinoma and in whom no metastases could be documented. The mean level for this group was 4.9±0.51 ng/ml (n = 43). In contrast, patients with documented metastases had a mean serum thyroglobulin level of 464.9±155.6 ng/ml (n = 6). The data support the thesis that in differentiated thyroid carcinoma serum thyroglobulin levels are elevated when metastases develop after initial treatment. It is proposed that the measurement of thyroglobulin in the serum represents a simple and valuable adjunct in the posttreatment follow-up of patients with differentiated thyroid cancer.
INTRODUCTION
Several previous investigations cast serious doubts on the theory that thyroglobulin is a secluded antigen confined to the thyroid gland in man (1) (2) (3) . In recent years data showing the presence of thyroglobulin in blood were extended to studies in patients with various pathologic states of the thyroid gland (4, 5) . Although the mechanism of the release of this thyroidal protein into the circulation is presently unknown, profound architectural and biological changes of the thyroid gland, which accompany neoplastic growth, could be responsible.
After the administration of 'I in patients with thyroid cancer, several authors have described the release of labeled iodinated proteins, among them thyroglobulin (6) (7) (8) (9) . The. recent development of a specific and sensitive radioimmunoassay for the measurement of serum thyroglobulin permitted us to investigate the presence of nonradioactive thyroglobulin in patients with thyroid carcinoma, thus avoiding the administration of radioisotopes in tracer or therapeutic amounts. The present study was undertaken to investigate human thyroglobulin (HTg)' levels in the serum of patients with differentiated thyroid carcinomas and those with medullary carcinoma of the thyroid. METHODS Radioimmunoassay. Serum thyroglobulin was determined in a double antibody radioimmunoassay, previously described, using a standard reference serum GA (40,000 ng/ml) which was appropriately diluted for the assay (4) . All (J. S.) displayed the same parallelism with the standard HTg preparation (Fig. 3) . Effect of therapy. In the prospective study data on seven patients in whom thyroglobulin levels were obtained before and after surgery and 'I therapy are shown in Fig. 4 . The mean preoperative serum thyroglobulin level was 154.1±66.7 ng/ml falling to a mean postoperative level of 6.4±1.5 ng/ml. The latter was obtained at a mean interval of 3.3 mo postsurgery.
Results of the retrospective study are shown in Fig.  5 different from the normal control group (P < 0.05). A value of 3.1 ng/ml was assigned to the sera with nondetectable levels (for interpretation of elevated serum thyroglobulin levels, see Discussion Section). Earlier studies measuring "I HTg in serum after "3I administration suggested thyroglobulin release into the circulation (6) (7) (8) (9) . However, quantitation of this protein in the circulation was not feasible at that time. Torrigiani, Doniach, and Roitt (5), studying unlabeled thyroglobulin in the serum, reported normal levels in the circulation of a limited number of patients with papillary thyroid carcinoma. In contrast, the present study discloses an elevated serum thyroglobulin level in patients with documented differentiated thyroid carcinoma before therapy and in patients with recurrence of such tumors.
The immunological characteristics of thyroglobulin in the serum of patients with differentiated thyroid carcinoma was identical with the standard preparation used. This is not surprising since thyroglobulin of carcinomatous tissue has been shown to have the same physicochemical characteristics and immunologic propSerum Thyroglobulin: Marker of Recurrent Thyroid Carcinomas erties as thyroglobulin derived from normal tissue (10) . The immunologic similarity of HTg in serum, tumor extract, and pleural fluid of patient J. S. provides additional evidence for this thesis.
Inasmuch as previous studies indicated that serum thyroglobulin levels are equally elevated in patients with Graves' disease and subacute thyroiditis (4, 11) , the test in its present form cannot be regarded as a specific one for the detection of thyroid cancer. This measurement, however, can be usefully applied in patients with histologically established thyroid carcinoma to assess the effective therapeutic manipulation of tumor mass if return of serum thyroglobulin levels into the normal range reflects total removal of the tumor mass. This is indeed the case since prospective and retrospective studies revealed that reduction of the HTg level toward normal or undetectable levels was associated with apparent complete tumor removal and -the absence of clinically or isotopically demonstrable metastases.
The amount of thyroid tumor-cell mass necessary to generate excessive circulating thyroglobulin levels (>20.7 ng/ml) is unknown. The data obtained from two subjects (R. M. and J. T.), where reintervention was performed notwithstanding normal serum levels, support the thesis that undetectable or normal thyroglobulin levels in a patient previously treated for thyroid cancer reflect the absence of detectable malignant tissue. Conversely, the finding of elevated serum thyroglobulin levels in our patients who were operated on previously invariably lead to the discovery of residual tumor or metastases. These observations emphasize the value of HTg measurements in the follow-up studies of patients with differentiated thyroid carcinoma.
The mechanism controlling the release of thyroglobulin into the circulation in both physiologic and pathologic conditions of the thyroid gland is unknown but is of considerable interest. Three Finally, evidence in favor of the third hypothesis (c) results from the observation that invasion of the thyroid by an epidermoid carcinoma of the larynx was accompanied by an elevated serum HTg level in patient E. C. (Table I) . If this third mechanism is operative, one would expect that any malignant process involving the thyroid gland could cause excessive thyroglobulin release. Previous studies by Shimaoka, Sokal, and Pickren (14) indicated that 10.9% of the patients with malignant lymphomas had involvement of the thyroid gland at autopsy. These investigators further indicated that non-Hodgkin's lymphomas had more frequent thyroidal involvement than Hodgkin's disease patients. Consistent with these pathologic studies are the findings of elevated serum thyroglobulin levels in patients M. E. and L. G., both with non-Hodgkin's lymphoma; this contrasted with the normal serum thyroglobulin level in patient E. F. with Hodgkin's disease. The elevated serum thyroglobulin level in patient G. V., who suffered from an epidermoid carcinoma of the lung, remains unexplained. Although clinical evidence of thyroid involvement was absent in these patients, confirmatory evidence by thyroid biopsy material would be required to render these observations meaningful, Clearly the present study leaves inconclusive evidence of the mechanisms responsible for the elevated HTg levels in the circulation of patients with thyroid cancer. Likely more than one mechanism is operative in the release of thyroglobulin from a thyroid gland harboring a malignant tumor.
The decrease in the serum HTg levels after successful treatment of differentiated thyroid carcinoma and the persistent elevation in the presence of metastases or regrowth make the measurement of serum thyroglobulin a simple and inexpensive clinical test in the follow-up and health care delivery of patients with established differentiated thyroid carcinoma.
